PMDA Cuts Review Lag With West In Half, But Application Lag Shows No Relief For Drug Launches In Japan
This article was originally published in PharmAsia News
Executive Summary
TOKYO - Japan's Pharmaceuticals and Medical Devices Agency has reduced its drug review lag in half since rolling out a plan two years ago to cut the drug lag, but products launched in the U.S. still hold a two-year head start compared to products launches in Japan, according to new estimates released by Japan's drug regulatory agency
You may also be interested in...
Japan's MHLW Approves Request For Needed Drugs That Can Bypass Clinical Trials
TOKYO - Japan's Ministry of Health, Labor and Welfare is urging manufacturers to develop drugs for Japan that are still unapproved or unapproved for additional indications already approved in the West. Some drugs considered highly medically necessary may qualify for approval via a known-art application without conducting new clinical trials in Japan. The move is part of the ministry's ongoing efforts to reduce the country's much talked about drug lag
Japan's MHLW Approves Request For Needed Drugs That Can Bypass Clinical Trials
TOKYO - Japan's Ministry of Health, Labor and Welfare is urging manufacturers to develop drugs for Japan that are still unapproved or unapproved for additional indications already approved in the West. Some drugs considered highly medically necessary may qualify for approval via a known-art application without conducting new clinical trials in Japan. The move is part of the ministry's ongoing efforts to reduce the country's much talked about drug lag
Asia Raises Bar for New Drugs, Manufacturers With Tougher CMC Reviews, GMP Inspections: A Look At Japan (Part 5)
The one Asian country with "first-tier" status, Japan may be on a par with the U.S. and the EU in the International Conference on Harmonization, but the country nevertheless faces challenges in the CMC and GMP arenas, said Pramod Kotwal of Merck, Sharpe and Dohme